Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes Mellitus Progressive Requirement for Multiple Therapies (UKPDS 49)

Article Abstract:

Many patients with type 2, or adult-onset diabetes, may need more than one treatment to control their blood sugar. Researchers compared the use of diet alone, insulin, sulfonylurea, or metformin in 4,075 patients who had just been diagnosed with type 2 diabetes. Each patient was randomly assigned to one of these treatments. After nine years of follow-up, only 8% of those on diet alone were able to control their blood sugar compared to 42% of those on insulin and 24% of those on sulfonylurea. Only 18% of obese patients on metformin were able to control their blood sugar.

Diet therapy, Insulin, Sulfonylurea compounds, Sulfonylureas

---

Effect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Trial

Article Abstract:

Combining metformin with rosiglitazone may improve blood sugar levels in patients with type 2 diabetes. These drugs are both used to treat type 2 diabetes but they have different actions. Therefore, they may complement each other. Researchers randomly assigned 348 patients with type 2 diabetes to take two different dosages of the drug combination or a placebo, or inactive substance. The drug combination was more effective in controlling blood sugar than placebo, and the higer dose was more effective than the lower dose. The treatment caused few side effects.

Drug therapy

---

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North

Article Abstract:

The efficacy and safety of rimonabant is compared with placebo each in conjunction with diet and exercise for sustained changes in weight and cardiometabolic risk factors over two years. The results suggest that 20 mg/d of rimonabant is effective in reducing body weight and waist circumference, while also favorably affecting several cardiometabolic risk factors.

United States, Overweight persons, Obesity, Dosage and administration, Weight reducing preparations, Anti-obesity agents

Similar abstracts:

• Abstracts: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. Pancreas transplantation and diabetic complications
• Abstracts: Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir
• Abstracts: Effects of theophylline on erythropoietin production in normal subjects in patients with erythrocytosis after renal transplantation
• Abstracts: Systems and diseases. Severe heart failure: a focus on the quality of care
• Abstracts: Preventing the uptake of smoking in young people. Mental health promotion in high-risk groups: identifying vulnerable groups and providing effective interventions can prevent mental health problems

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.